Asthma control in adults

British Medical Journal

Volumn 332, Issue 7544, 2006, Pages 767-771

  Rees, John ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; GAMMA INTERFERON; INTERLEUKIN 1BETA; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NITRIC OXIDE; PHOSPHODIESTERASE IV INHIBITOR; SALMETEROL; STEROID; TUMOR NECROSIS FACTOR ALPHA; ANTIASTHMATIC AGENT;

ASTHMA; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MECHANISM; HUMAN; LUNG FUNCTION; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADULT; BRONCHITIS; PATIENT CARE PLANNING; PRACTICE GUIDELINE;

ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHITIS; HUMANS; PATIENT CARE PLANNING; PATIENT COMPLIANCE; PRACTICE GUIDELINES;

EID: 33645578341     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.332.7544.767     Document Type: Review

References (24)

1. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-78.
2. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2003;58(suppl 1):i1-94.
3. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJH, Pauwels RW, et al. Can guideline-defined asthma control be achieved? Am J Respir Crit Care Med 2004;170:836-44.
4. Carlton BG, Lucas DO, Ellis EF, Conboy-Ellis K, Shoheiber O, Stempel DA. The status of asthma control and asthma prescribing practices in the United States: results of a large prospective asthma control survey of primary care practices. J Asthma 2005;42:529-35.
5. Steven K, Neville RG, Hoskins G, Sullivan FM, Drummond N, Alder EM. The RCP's 'three key questions' for asthma: review of practical use. Br J Community Nurs 2002;7:300-3.
6. Laitinen LA, Laitinen A, Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 1993;147:697-704.
7. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med 1999;159:1043-51.
8. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21.
9. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171:912-30.
10. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005;352:2163-73.
11. Ducharme FM, Di Salvio F. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2004;(1):CD002314.
12. Ducharme F, Schwartz Z, Kakuma R. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2004;(1):CD003133.
13. Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-11.
14. Ram FSF, Cates CJ, Ducharme FM. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2005;(1):CD003137.
15. Bisgard H, Szefler S. Long acting β2 agonists and paediatric asthma. Lancet 2006;367:286-8.
16. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The salmeterol multicenter asthma research trial. Chest 2006;129:15-26.
17. Adams N, Bestall JM, Lasserson TJ, Jones PW. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 2005;(3):CD002310.
18. Powell H, Gibson PG. High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. Cochrane Database Syst Rev 2003;(4):CD004109.
19. Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroids to prevent asthma exacerbations: randomised controlled trial. Lancet 2004;363:271-5.
20. Aalbers R, Backer V, Kava TT, Omenaas ER, Sandstrom T, Jorup C, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004;20:225-40.
21. Fitzgerald JM, Boulet LP, Follows RM. The CONCEPT trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther 2005;27:393-406.
22. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
23. Fleming SL, Pagliari C, Churchill R, Shuldham CM, McKean M. Psychotherapeutic interventions for adults with asthma. Cochrane Database Syst Rev 2004;(1):CD002982.
24. Toelle BG, Ram FS. Written individualised management plans for asthma in children and adults. Cochrane Database Syst Rev 2004;(2):CD002171.